Registry platform for patients with blood cancers in Germany

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The RUBIN project aims to establish a national, prospective, longitudinal registry to collect uniform data on patients with hematological malignancies in Germany. This observational study will document patient characteristics, treatment regimens, and disease progression while also gathering patient-reported outcomes. The registry will analyze the effectiveness of various treatments and identify unmet needs in routine care. Additionally, it will create a decentralized biobank for future research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Confirmed diagnosis of the respective NHL
* If patient is alive: signed written informed consent

  * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.
  * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.

Exclusion Criteria:

* No systemic therapy for respective lymphoid malignancy.

Where it's running

• Praxis für Interdisziplinäre Hämatologie und Onkologie
  Freiburg im Breisgau, Germany Recruiting

Study contacts

• Study coordinator: Martina Jänicke, Dr.
• Email: rubin@iomedico.com
• Phone: +4976115242

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating NX-5948 for advanced B-cell cancers

  This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.

  Recruiting at 53 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 61 other locations · NCT05131022

• Evaluating NX-2127 for adults with advanced B-cell cancers

  This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.

  Recruiting at 7 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 15 other locations · NCT04830137

• Testing EXS73565 for patients with relapsed or refractory B-cell cancers

  This study is testing a new oral medication called EXS73565 to see if it can help adults with B-cell cancers that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1 Exscientia AI Limited · Tbilisi and 16 other locations · NCT06980116

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• Safety testing of LTZ-301 in adults with relapsed or refractory B‑cell non-Hodgkin lymphoma

  This trial will test whether LTZ-301 is safe and how it behaves in adults whose B‑cell non-Hodgkin lymphoma has come back or not responded after at least two prior treatments.

  Recruiting at 6 sites Phase 1 LTZ Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07121946

• Real-world data collection for lymphoma and patient survival

  This study is trying to gather real-life information from lymphoma patients to see how different factors affect their treatment success and long-term survival.

  Recruiting at 37 sites Hospices Civils de Lyon · Arras and 36 other locations · NCT03869619

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.